Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.

Stayner C, Shields J, Slobbe L, Shillingford JM, Weimbs T, Eccles MR.

Nephrology (Carlton). 2012 Nov;17(8):739-47. doi: 10.1111/j.1440-1797.2012.01639.x.

PMID:
22725947
2.

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ.

Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23.

3.

Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.

Stayner C, Iglesias DM, Goodyer PR, Ellis L, Germino G, Zhou J, Eccles MR.

Hum Mol Genet. 2006 Dec 15;15(24):3520-8. Epub 2006 Nov 2. Erratum in: Hum Mol Genet. 2009 Apr 15;18(8):1543.

PMID:
17082250
4.

Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.

Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F, Crews CM.

Nephrol Dial Transplant. 2010 Jul;25(7):2187-94. doi: 10.1093/ndt/gfp777. Epub 2010 Feb 4.

5.

Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Mekahli D, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, DechĂȘnes G, Ong AC, Wilmer MJ, van den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H.

Pflugers Arch. 2014 Aug;466(8):1591-604. doi: 10.1007/s00424-013-1394-x. Epub 2013 Nov 6.

PMID:
24193408
6.

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Shillingford JM, Piontek KB, Germino GG, Weimbs T.

J Am Soc Nephrol. 2010 Mar;21(3):489-97. doi: 10.1681/ASN.2009040421. Epub 2010 Jan 14.

7.

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.

Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL.

Kidney Int. 2010 Oct;78(8):754-61. doi: 10.1038/ki.2010.250. Epub 2010 Aug 4.

8.

Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.

Leonhard WN, Zandbergen M, Veraar K, van den Berg S, van der Weerd L, Breuning M, de Heer E, Peters DJ.

J Am Soc Nephrol. 2015 Jun;26(6):1322-33. doi: 10.1681/ASN.2013080864. Epub 2014 Oct 31.

9.

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.

Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S.

Hum Mol Genet. 2008 Jun 1;17(11):1505-16. doi: 10.1093/hmg/ddn039. Epub 2008 Feb 7.

10.

Pkd1 is required for male reproductive tract development.

Nie X, Arend LJ.

Mech Dev. 2013 Nov-Dec;130(11-12):567-76. doi: 10.1016/j.mod.2013.07.006. Epub 2013 Aug 9.

11.

An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.

Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL.

Hum Mol Genet. 2014 Sep 15;23(18):4919-31. doi: 10.1093/hmg/ddu208. Epub 2014 May 8.

12.

Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.

Zhou X, Fan LX, Sweeney WE Jr, Denu JM, Avner ED, Li X.

J Clin Invest. 2013 Jul;123(7):3084-98. doi: 10.1172/JCI64401. Epub 2013 Jun 17.

13.

Pkd1 and Pkd2 are required for normal placental development.

Garcia-Gonzalez MA, Outeda P, Zhou Q, Zhou F, Menezes LF, Qian F, Huso DL, Germino GG, Piontek KB, Watnick T.

PLoS One. 2010 Sep 16;5(9). pii: e12821. doi: 10.1371/journal.pone.0012821.

14.

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M.

Hepatology. 2010 May;51(5):1778-88. doi: 10.1002/hep.23511.

15.

Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.

Fan LX, Li X, Magenheimer B, Calvet JP, Li X.

Kidney Int. 2012 Jan;81(1):76-85. doi: 10.1038/ki.2011.296. Epub 2011 Sep 7.

16.

Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects.

Lu W, Shen X, Pavlova A, Lakkis M, Ward CJ, Pritchard L, Harris PC, Genest DR, Perez-Atayde AR, Zhou J.

Hum Mol Genet. 2001 Oct 1;10(21):2385-96.

PMID:
11689485
17.

Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Happé H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ.

Hum Mol Genet. 2009 Jul 15;18(14):2532-42. doi: 10.1093/hmg/ddp190. Epub 2009 Apr 28.

PMID:
19401297
18.

Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation.

Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson C, Brent G, Zhou J.

Nat Genet. 1997 Oct;17(2):179-81.

PMID:
9326937
19.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

PMID:
26823553
20.

Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.

Bastos AP, Onuchic LF.

Braz J Med Biol Res. 2011 Jul;44(7):606-17. Epub 2011 May 27. Review.

Supplemental Content

Support Center